Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance ... Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. 詳細を表示
DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat...
-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2449 | -12.1538461538 | 2.015 | 2.05 | 1.625 | 1135090 | 1.78255876 | CS |
4 | -0.0249 | -1.38718662953 | 1.795 | 3.02 | 1.625 | 1542312 | 2.20557524 | CS |
12 | 0.7101 | 66.9905660377 | 1.06 | 3.02 | 0.808 | 3003412 | 1.8057037 | CS |
26 | 0.6701 | 60.9181818182 | 1.1 | 3.02 | 0.808 | 1542205 | 1.74425567 | CS |
52 | 0.0801 | 4.73964497041 | 1.69 | 3.02 | 0.808 | 967083 | 1.71092542 | CS |
156 | 1.3001 | 276.617021277 | 0.47 | 3.1305 | 0.175 | 930520 | 0.87141265 | CS |
260 | -1.1199 | -38.7508650519 | 2.89 | 6.47 | 0.175 | 3604210 | 1.35832557 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約